These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 26784451

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
    Feldt S, Schüssel K, Quinzler R, Franzmann A, Czeche S, Ludwig WD, Schulz M.
    Eur J Cancer; 2012 May; 48(7):974-81. PubMed ID: 22382202
    [Abstract] [Full Text] [Related]

  • 4. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K.
    Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
    [Abstract] [Full Text] [Related]

  • 5. Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
    Walko CM, Aubert RE, La-Beck NM, Clore G, Herrera V, Kourlas H, Epstein RS, McLeod HL.
    Oncologist; 2017 Feb; 22(2):208-212. PubMed ID: 28167571
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hypothyroidism during treatment with tyrosine kinase inhibitors.
    Zygulska AL, Krzemieniecki K, Sowa-Staszczak A.
    Endokrynol Pol; 2012 Feb; 63(4):302-6. PubMed ID: 22933166
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

  • 11. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Juengel E, Kim D, Makarević J, Reiter M, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.
    J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
    Mulder SF, Bertens D, Desar IM, Vissers KC, Mulders PF, Punt CJ, van Spronsen DJ, Langenhuijsen JF, Kessels RP, van Herpen CM.
    BMC Cancer; 2014 Mar 24; 14():219. PubMed ID: 24661373
    [Abstract] [Full Text] [Related]

  • 14. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ.
    Curr Top Med Chem; 2012 Mar 24; 12(15):1649-59. PubMed ID: 22978339
    [Abstract] [Full Text] [Related]

  • 15. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC.
    Cancer; 2011 Feb 01; 117(3):534-44. PubMed ID: 20845482
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
    Jang S, Zheng C, Tsai HT, Fu AZ, Barac A, Atkins MB, Freedman AN, Minasian L, Potosky AL.
    Cancer; 2016 Jan 01; 122(1):124-30. PubMed ID: 26439451
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.
    Chemotherapy; 2012 Jan 01; 58(6):468-74. PubMed ID: 23548259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.